Coherus Oncology (CHRS) Non Operating Income (2013 - 2026)

Coherus Oncology has disclosed Non Operating Income across 14 years of filings, most recently posting $1.4 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $1.4 million, up 649.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 million (up 66.48% YoY), and the FY2025 annual result was $7.0 million, down 8.03% from the prior year.
• Non Operating Income came in at $1.4 million for Q1 2026 at Coherus Oncology, down from $1.8 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $2.9 million in Q2 2025 to a low of -$129000.0 in Q4 2023.
• The 5-year median for Non Operating Income is $1.6 million (2023), against an average of $1.5 million.
• Peak annual rise in Non Operating Income reached 5300.0% in 2023, while the deepest fall reached 106.42% in 2023.
• Coherus Oncology's Non Operating Income stood at $2.0 million in 2022, then sank by 106.42% to -$129000.0 in 2023, then surged by 1032.56% to $1.2 million in 2024, then surged by 48.13% to $1.8 million in 2025, then declined by 21.32% to $1.4 million in 2026.
• The last three Non Operating Income figures came in at $1.4 million (Q1 2026), $1.8 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.